Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ticagrelor

- PMLiVE

UK rations AZ’s paediatric flu vaccine after delivery delays

Supplies may be limited as flu season begins

AstraZeneca AZ

AZ’s Farxiga gets heart failure prevention okay from FDA

Important win for AZ as it chases down market leader Jardiance

- PMLiVE

AZ and Daiichi get speedy review for rival to Roche’s HER2 drugs

Could add to AZ's portfolio of emerging cancer drugs

What is changing in cardiovascular disease care?

Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma

Wilmington Healthcare

- PMLiVE

Aspen to pay millions to NHS following drug pricing investigation

CMA found company colluded to create a monopoly in UK market

- PMLiVE

UK bans some drug exports to preserve NHS stocks

Insists the move is not related to Brexit

- PMLiVE

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Will also not be included in the Cancer Drugs Fund

AstraZeneca AZ

AstraZeneca sells Losec rights as part of refocus strategy

Funds will be diverted to bolster main therapy areas

- PMLiVE

GSK’s Zejula challenges AZ/Merck’s Lynparza in PARP inhibitor category

New data in ovarian cancer creates potential for market battle

- PMLiVE

Hancock says UK will consider mandatory vaccinations

Conservatives' also announce £13bn investment for hospitals over next decade

- PMLiVE

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Blow to patients who have dubbed the treatment 'life-saving'

- PMLiVE

Innate Pharma and AstraZeneca take monalizumab into phase 3

AZ hopes to catch up to rivals using the French biotech's candidate

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links